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ABSTRACT
Objectives: To explore whether changes in a
composite (power Doppler/greyscale ultrasound
(PDUS)) synovitis score, developed by the OMERACT-
EULAR-Ultrasound Task Force, predict disease activity
outcomes in rheumatoid arthritis (RA).
Methods: Patients with RA who were methotrexate
inadequate responders starting abatacept were evaluated.
Individual joint PDUS scores were combined in the Global
OMERACT-EULAR Synovitis Score (GLOESS) for
metacarpophalangeal joints (MCPs) 2–5, all joints (22
paired) and a reduced (9 paired) joint set. The predictive
value of changes in GLOESS at week 1–16 evaluations for
clinical status and response (Disease Activity Score (DAS)
28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2;
DAS28(CRP) ≥1.2 improvement) up to week 24, and
correlations between DAS28 and GLOESS were assessed.
Results: Eighty-nine patients completed the 24-week
treatment period. Changes in GLOESS (MCPs 2–5) from
weeks 1 to 16 were unable to predict DAS28 outcomes
up to week 24. However, significant improvements in
GLOESS (MCPs 2–5) were observed at week 12 in
patients with DAS28 ≥1.2 improvement at week 24
versus those who did not achieve that clinical response.
In patients achieving DAS28 ≥1.2 improvement or DAS28
≤3.2 at week 24, changes in GLOESS (22 and 9 paired
joint sets) were greater in patients who already achieved
DAS28 ≥1.2 at week 12 than in those who did not. No
significant correlations were found between changes in
DAS28 and GLOESS definitions at any time point.
Conclusions: PDUS was not correlated with clinical
status or response as measured by DAS28-derived
criteria, and PDUS changes were not predictive of clinical
outcome. The discrepancies require further exploration.
Trial registration number: NCT00767325; Results.
INTRODUCTION
Recently, the European League Against
Rheumatism (EULAR) recommended that
the treatment of rheumatoid arthritis (RA)
should target remission or low disease activity
in every patient, with adjustments in therapy
if there is no improvement within 3 months
or if the target is not reached within
6 months.1 To follow this treat-to-target strat-
egy, rheumatologists need to tightly monitor
Key messages
What is already known about this subject?
▸ Power Doppler with greyscale ultrasound (PDUS)
is a non-invasive, bedside, objective and sensitive
tool for visualising synovial inflammatory joint
changes in rheumatoid arthritis (RA) that were
not detected by conventional clinical and radio-
graphic examinations.
What does this study add?
▸ The primary analysis of the APPRAISE study of
abatacept treatment in RA demonstrated the
responsiveness of the composite PDUS Global
OMERACT-EULAR Synovitis Score (GLOESS)
when applied at a patient level, showing the rapid
onset of action of abatacept at 1 week. Although
improvements were also demonstrated using
DAS28, a clinical improvement of ≥1.2 was
reached only after 1 month. The current analyses
demonstrated a lack of correlation between
GLOESS outcomes and clinical status or response
as measured by DAS28-derived criteria, which is
an important finding to underline.
How might this impact on clinical practice?
▸ The lack of correlation between PDUS and clin-
ical measures suggests that these tools evaluate
different aspects of disease activity in RA and
should be considered complementary in clinical
practice.
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patients to ensure that they reach the target using clin-
ical indices.
The combined use of power Doppler and greyscale
ultrasound (PDUS) represents an easy, non-invasive,
bedside imaging modality that has been demonstrated
to be an objective and sensitive tool for visualising syn-
ovial inﬂammatory joint changes in RA that were not
detected by conventional clinical and radiographic
examinations.2–6 Several factors, such as machine
characteristics and operator-dependent interpretation,
are known to inﬂuence the sensitivity of detecting syno-
vitis by PDUS. Therefore, the Outcome Measures in
Rheumatology-Ultrasound (OMERACT-US) Task Force,
with funding from EULAR, developed a standardised
composite PDUS scoring system for synovitis in RA
designed to be applicable to all joints and consistent
between machines. To facilitate the assessment of global
synovial activity, the group also developed a patient
PDUS activity score, the Global OMERACT-EULAR
Synovitis Score (GLOESS), calculated from the sum of
composite PDUS scores for all joints examined. GLOESS
has since been validated in cross-sectional and longitu-
dinal data sets.7
APPRAISE was the ﬁrst prospective, multicentre, inter-
national study to use this composite PDUS score at joint
and patient levels to measure the early signs of response to
treatment with abatacept in biological-naïve adult patients
with active RA despite methotrexate (MTX) therapy.8 This
study demonstrated the responsiveness of the composite
PDUS GLOESS when applied at a patient level, showing
the rapid onset of action of abatacept, independently of
the number of joints examined. The responsiveness of
GLOESS equalled that of clinical assessment by Disease
Activity Score (DAS)28 C reactive protein (CRP). Despite
the clear capability of PDUS for monitoring the effects of
treatment in RA demonstrated in APPRAISE and other
published clinical studies,9–12 discordant correlations have
been found between PDUS scores and clinical outcomes
measured at the same time point.13 14
The aim of this paper was to present the results of pre-
deﬁned secondary, exploratory and post hoc analyses,
which investigated whether changes in GLOESS at assess-
ments from weeks 1 to 16 were predictive of clinical
response measured by DAS28 at later assessments, and
also whether GLOESS could differentiate between mul-
tiple deﬁnitions of clinical response or status using
DAS28 up to week 12 and at week 24.
METHODS
The APPRAISE study methodology has been reported
previously.8 Brieﬂy, APPRAISE (NCT00767325) was a
24-week, Phase IIIb, open-label, multicentre, single-arm
study investigating the responsiveness of the
OMERACT-EULAR-composite PDUS score in
biological-naïve patients (≥18 years) with active RA and
an inadequate response to MTX therapy starting abata-
cept. Patients received intravenous abatacept
(approximately 10 mg/kg) at baseline (day 1), and at
weeks 2, 4, 8, 12, 16, 20 and 24, in addition to stable
doses of concomitant MTX (≥15 mg/week). Oral cor-
ticosteroid use (stable dose of ≤10 mg prednisone/day)
was permitted. Patients had American College of
Rheumatology (ACR)-deﬁned RA (1987 classiﬁcation
criteria) for at least 6 months, and were receiving MTX
(≥15 mg/week) for at least 3 months prior to baseline,
with a stable MTX dose for at least 28 days before base-
line (except in cases of intolerance). Patients were
required to have active disease, deﬁned by a baseline
DAS28 (CRP) score of >3.2 or tender and swollen joint
counts (TJC and SJC) of ≥6 and a CRP level of greater
than the upper normal limit.
PDUS evaluations
Patients underwent bilateral PDUS examinations of
metacarpophalangeal joints (MCPs) 2–5 at screening
and baseline, and of 44 (22 paired) joints (MCPs 1–5,
proximal interphalangeal joints (PIPs) 1–5, wrist, elbow,
shoulder (glenohumeral), knee, ankle (tibiotalar), hind
foot (talonavicular and calcaneocuboidal) and metatar-
sophalangeal joints (MTPs) 1–5) at baseline (day 1),
and at weeks 1, 2, 4, 6, 8, 12, 16, 20 and 24. The PDUS
examinations were performed at each site by an inde-
pendent expert in musculoskeletal ultrasound who was
blinded to the clinical evaluations. Medium-level to high-
level ultrasound machines were used (Esaote Technos
MPX, MyLab 70, Toshiba Aplio, GE Logic (series 5, 7, 9
and E 9) or Siemens Acuson Antares), employing high-
frequency (12–18 MHz) transducers. Doppler para-
meters were adjusted according to the device used
(range of pulse repetition frequency 400–800 Hz;
Doppler frequency 7–11.1 MHz).8
The presence of hypoechoic synovial hyperplasia (SH)
and joint effusion ( JE), both assessed using greyscale,
and of synovial vascularisation, assessed using power
Doppler (PD), were scored using semiquantitative scales.
The presence of synovitis (SH and PD, without JE) was
scored for each joint according to the semiquantitative
OMERACT-EULAR-US composite PDUS scale, giving a
score of 0–3 for each joint. GLOESS was calculated for
MCPs 2–5 of both hands and for the 22 paired joints,
using the sum of the composite PDUS scores for all
joints examined, giving a potential score of 0–24 for
MCPs 2–5, and of 0–132 for the 22 paired joints. A new
reduced, 9 paired joint set score (including both large
and small joints: shoulder, elbow, wrist, MCP1, MCP4,
PIP2, knee, MTP3 and MTP5) was also determined
using principal component analysis and was found to
adequately represent the comprehensive 22 paired joint
GLOESS.8
Clinical evaluations
DAS28 (CRP) was evaluated at baseline (day 1) and at
weeks 1, 2, 4, 6, 8, 12, 16, 20 and 24. Mean change in
DAS28 from baseline, the proportion of patients achiev-
ing DAS28 improvement ≥1.2, and the proportion of
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patients achieving DAS28 <2.6 or DAS28 ≤3.2 were
assessed.
Statistical analyses
Receiver operating characteristic (ROC) analysis was
used to assess whether changes in GLOESS (MCPs 2–5)
or in any of the component scores (SH, JE and PD) at
any of the assessments from weeks 1 to 16 were predict-
ive of clinical status (DAS28 <2.6; DAS28 ≤3.2) and
response (improvement in DAS28 ≥1.2) at later time
points. An area under the ROC curve of ≥0.7 was con-
sidered acceptable for prediction of disease activity, as
suggested by Hosmer and Lemeshow.15 Descriptive statis-
tics were used to compare changes from baseline to
weeks 12 and 24 in GLOESS (MCPs 2–5) and the com-
ponent scores in patients who achieved a clinical status
or response at week 24 versus those who did not.
Data were analysed to see if PDUS could identify
patients with a meaningful clinical status or response at
week 12 versus week 24. In patients achieving DAS28 ≤3.2
or improvement in DAS28 ≥1.2 at week 24, descriptive
statistics were used to assess whether changes in GLOESS
at week 12 could differentiate patients who also achieved
DAS28 ≥1.2 improvement at week 12 from those who did
not. These analyses were completed using MCPs 2–5, the
22 paired and reduced 9 paired joint sets.
Correlation analyses
To explore further the relationship between GLOESS
and clinical response, additional post hoc correlation
analyses were performed using Pearson’s (parametric)
or Spearman’s (non-parametric) correlation coefﬁcient
with 95% CIs. Correlations between changes at different
time points were assessed within and between GLOESS
and DAS28 outcomes. Details of the correlation analyses
performed are presented in online supplementary table
S1. Effect size, expressed as standardised response
means (SRM) of GLOESS and DAS28, was investigated
on the basis of mean changes from baseline to weeks 1,
12 and 24. Correlation analyses using absolute values
and changes from baseline were completed with the last
observation carried forward to quantify the treatment
effect of abatacept plus MTX over time. Analyses were
performed using all available GLOESS and component
scores (no imputation of missing data). Missing DAS28
values were imputed. No correction for multiple statis-
tical tests was applied.
RESULTS
In total, 89 (86%) of the 104 patients enrolled between
December 2008 and October 2011 completed the
24-week, open-label treatment period. Demographic and
baseline characteristics of the study population have
been reported previously, as well as the results on the
responsiveness of the score.8 In patients with DAS28
measurements available at week 12 and week 24 (n=98,
which included 9 patients with DAS28 measurements
but who had not completed the open-label treatment
period), the number of patients who achieved DAS28
≥1.2 improvement at week 12 and who also achieved
DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24
were 50/98 (51%) and 37/98 (38%), respectively, while
the number of patients who did not achieve DAS28 ≥1.2
improvement at week 12 but achieved DAS28 ≥1.2
Figure 1 Mean change from baseline in GLOESS and
components at week 12 in patients who did, or did not,
achieve (A) DAS28 ≥1.2 improvement, (B) DAS28 ≤3.2 or (C)
DAS28 <2.6 at week 24. Error bars represent SEM. DAS28,
Disease Activity Score 28; GLOESS, Global
OMERACT-EULAR Synovitis Score; MCPs,
metacarpophalangeal joints. GLOESS and the component
scores were calculated for MCPs 2–5 using both hands,
giving a potential score of 0–24.
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improvement or DAS28 ≤3.2 at week 24 were 10/98
(10%) and 10/98 (10%), respectively.
Relationship between GLOESS and meaningful clinical
status or response
All patients showed an improvement in GLOESS (MCPs
2–5) at week 12, regardless of clinical status or response
at week 24 (ﬁgure 1). In particular, signiﬁcantly greater
improvements were observed from baseline to week 12
in GLOESS and in all three component scores (SH, JE
and PD) in patients who achieved DAS28 ≥1.2 improve-
ment at week 24 compared with those who did not
(ﬁgure 1A). However, the ROC area under the curve
never reached or exceeded the predeﬁned cut-off of 0.7;
therefore, changes in GLOESS and in all component
scores for MCPs 2–5 at any time point up to week 16
were unable to adequately predict clinical status or
response at week 24 or at any other time point, regard-
less of criteria used. Moreover, no difference was
observed in the mean decrease of GLOESS (MCPs 2–5)
from baseline to week 12 in patients who achieved or
did not achieve DAS28 <2.6 or DAS28 ≤3.2 at week 24
(ﬁgure 1B, C). The only component score that was dif-
ferent in patients who reached DAS28 <2.6 or DAS28
≤3.2 at week 24 versus those who did not was the JE
score. Similar results were observed using the 22 paired
and 9 paired joint sets (table 1).
In patients who achieved DAS28 ≤3.2 or DAS28 ≥1.2
improvement at week 24, changes from baseline to week
12 in GLOESS for the 22 paired and 9 paired joint sets
were able to detect some differences between patients
who achieved DAS28 ≥1.2 improvement at week 12
versus those who did not (ﬁgure 2).
Correlation analyses
Previous correlation analyses demonstrated the absence
of correlations between changes in DAS28 from baseline
with changes in GLOESS or component scores; very low
correlations between GLOESS (MCPs 2–5) or compo-
nent scores and swollen joint counts (SJC) and/or
tender joint counts (TJC); no correlations between early
changes in GLOESS or components and changes in the
sum of swollen joints at week 12 or 24.8
When we looked at correlations within each assess-
ment method (ie, between DAS28 scores at different
time points or between GLOESS scores at different time
points), moderate-to-high positive correlations were
observed between improvements up to week 12 and
improvements at week 24 in DAS28 (table 2). Moderate-
to-high positive correlations were also observed between
changes in GLOESS from baseline to weeks 2, 4, 8 and
Table 1 Mean change in GLOESS from baseline to weeks 12 and 24 in patients with DAS28 ≤3.2 at week 24, with or
without DAS28 ≥1.2 improvement at week 12
DAS28 ≥1.2 improvement at week 12
and DAS28 ≤3.2 at week 24
DAS28 <1.2 change at week 12
and DAS28 ≤3.2 at week 24
MCPs 2–5 joint set Week 12 −4.2 (−5.8 to −2.5) −4.3 (−6.2 to −2.4)
Week 24 −5.5 (−7.0 to −4.0) −6.9 (−10.6 to −3.2)
22 paired joint set Week 12 −12.6 (−17.2 to −8.0) −10.6 (−16.7 to −4.5)
Week 24 −17.1 (−22.4 to −11.8) −18.2 (−28.6 to −7.8)
Reduced (9 paired joints) set Week 12 −6.1 (−8.0 to −4.1) −4.3 (−6.2 to −2.4)
Week 24 −7.3 (−9.6 to −5.1) −6.7 (−11.1 to −2.3)
Data are mean change (95% CI).
DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; MCP, metacarpophalangeal joint.
Figure 2 Mean change from baseline in GLOESS at week
12 in patients who did, or did not, also achieve DAS28 ≥1.2
improvement, in (A) patients who achieved DAS28 ≤3.2 at
week 24 or (B) patients who achieved DAS28 ≥1.2
improvement at week 24. Patients who discontinued due to
lack of efficacy, adverse event or withdrawal of consent are
considered as non-responders. Error bars represent SEM.
DAS28, Disease Activity Score 28; GLOESS, Global
OMERACT-EULAR Synovitis Score; MCPs,
metacarpophalangeal joints. GLOESS was calculated for each
joint set using both hands, giving a potential score of 0–24 for
MCPs 2–5, 0–132 for the 22 paired joint set, and 0–54 for the
reduced (9 paired) joint set.
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12 and change in GLOESS (both 22 paired and 9
paired joint sets) from baseline to week 24 (table 3).
However, changes in GLOESS during the ﬁrst week of
treatment were weakly correlated with overall change in
GLOESS during the 24-week treatment period. Overall,
SRM values for GLOESS (MCPs 2–5, 22 paired and
reduced 9 paired joint sets) were smaller than SRM
values for DAS28 for mean change from baseline at
weeks 1, 12 and 24 (see online supplementary tables S1
and S2). A summary of the ﬁndings of the correlation
analysis is presented in table 4.
DISCUSSION
This study demonstrated an almost complete absence of
association between ultrasound and clinical status or
response in RA in patients starting treatment with abata-
cept. Whereas both modalities (PDUS and composite
DAS) were responsive to treatment in this setting,8 the
extent of response in one modality was not reﬂected in
the extent of improvement in the other. In addition,
early changes in GLOESS were not predictive of a good
clinical status or response at 24 weeks. This lack of cor-
relation or predictive capacity was not caused by incon-
sistency of results over time, as correlations within
modality (ie, between early and late GLOESS, and
between early and late DAS28 outcomes) were moderate
to strong, as were SRM values. This lack of correlation is
a novel ﬁnding, although previous studies have reported
a lack of complete overlap between ultrasound-assessed
disease activity and composite clinical measures,16–18
with one study suggesting that the simpliﬁed disease
activity index is closer to PDUS assessment of disease
state than DAS28.19 Another study found that ultrasound
had low correlations with disease activity assessment at
baseline, while after 12 months of adalimumab treat-
ment, correlation coefﬁcients had improved.20
Several explanations can be discussed for interpreting
these results. First, the sensitivity to change as estimated by
SRM calculations (which was better for DAS28 than for
GLOESS, whatever the joint set) can suggest that clinical
efﬁcacy measures were more sensitive to change than
ultrasound. However, these discrepancies can also be
explained by the wider SD for PDUS assessments than
DAS28, as the SRM calculation is dependent on the SD of
the measure.21 Second, we identiﬁed some patients who
appeared to have a complete disconnect between GLOESS
(and component scores) and DAS28, SJC or TJC (data not
shown). This may be explained by the greater sensitivity of
PDUS for detecting minimal and/or subclinical synovitis
compared with clinical examination. A recent paper con-
ﬁrmed that, in patients in disease remission (clinical
disease activity index ≤2.8), only grade 3 (severe)
PDUS-assessed synovitis correlated with clinical examin-
ation and clinical activity scores, demonstrating that when
clinical evaluation is taken as the gold standard, the cap-
ability of PDUS is reduced.22 A number of patients with
RA can score pain and TJC higher than PDUS assessments
would indicate. Finally, the severity of PDUS synovitis
(MCPs 2–5) was relatively low (grade 1–2) at baseline, sup-
porting the apparent discordance between clinical and
PDUS evaluations when assessing whether a joint was
inﬂamed or not. This latter aspect requires further investi-
gation. Overall, this study suggests that PDUS and DAS28
capture different aspects of disease activity that present dif-
ferent kinetics of response over time.
The ﬁndings of this study should be considered as
exploratory, and the limitations of the study have been
discussed previously and include the single-arm, open-
label design, the sample size and the variables relating
to the technology used.8 The analyses presented here
are intended to inform future prospective studies of
PDUS in RA. The present study suggests that PDUS
scores improve as a consequence of effective treatment,
but DAS28 cannot be used as a comparator for ultra-
sound, as they do not reﬂect the same aspects of the
arthritis inﬂammatory process. The use of other mea-
sures of disease activity that are more stringent than
DAS28, such as Clinical Disease Activity Index (CDAI)
and Simple Disease Activity Index (SDAI), would prob-
ably provide better correlation results.
Table 3 Correlation between changes from baseline in GLOESS up to week 12 and change from baseline to week 24
Pearson’s correlation coefficient (95% CI)
n 22 paired joint set n Reduced (9 paired) joint set
Baseline to week 1 79 0.29 (0.07 to 0.48) 75 0.27 (0.05 to 0.47)
Baseline to week 2 86 0.37 (0.17 to 0.54) 82 0.35 (0.14 to 0.52)
Baseline to week 4 84 0.61 (0.46 to 0.73) 79 0.53 (0.35 to 0.67)
Baseline to week 8 82 0.62 (0.46 to 0.74) 77 0.61 (0.44 to 0.73)
Baseline to week 12 82 0.71 (0.57 to 0.80) 81 0.62 (0.46 to 0.74)
GLOESS, Global OMERACT-EULAR Synovitis Score.
Table 2 Correlation between changes from baseline in
DAS28 up to week 12 and change from baseline to week 24
n
Pearson’s correlation
coefficient (95% CI)
Baseline to week 1 82 0.37 (0.16 to 0.54)
Baseline to week 2 84 0.44 (0.25 to 0.60)
Baseline to week 4 87 0.61 (0.45 to 0.72)
Baseline to week 8 86 0.66 (0.51 to 0.76)
Baseline to week 12 87 0.71 (0.59 to 0.80)
DAS28, Disease Activity Score 28.
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In conclusion, PDUS was a responsive tool of disease
activity in patients with RA starting abatacept plus MTX,
but the extent of PDUS response was not correlated with
clinical status or response, as measured by DAS28 derived
criteria, and early PDUS changes were not predictive of a
later good clinical outcome. This suggests that PDUS
adds independent information on treatment response,
and its contribution should be explored further.
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Table 4 Correlation analysis summary
Variables Correlation
Changes in DAS28 up to week 12 vs week 24 Moderate-to-high positive correlations (table 2)
Changes in GLOESS (22 paired joints, reduced 9 paired joint set) from
baseline up to week 12 vs baseline to week 24
Moderate-to-high positive correlations (table 3)
Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired
joint set) from baseline up to week 12 and lower levels of synovitis*
at week 24
Low-to-moderate negative correlations (see
online supplementary table S2)
Changes in GLOESS at week 1 and changes in GLOESS during the
entire treatment period (baseline to week 24)
Low correlation
Changes in DAS28 and changes in GLOESS (MCPs 2–5, 22 paired
joints, reduced 9 paired joint set, 28 joints†) or component scores
(SH, PD, JE) from baseline
No correlation at any time points
GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC Very low correlation at all time points
GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs TJC Very low correlation at all time points
GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC
+ TJC combined
Very low correlation at all time points
Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint
set) or components (SH, PD, JE) up to week 4 vs change in the sum of
swollen joints (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) at
weeks 12 and 24
No correlation
*Defined by a GLOESS at week 24 that was less than the median GLOESS at that time point.
†The 28 joints assessed for tenderness and swelling as part of the DAS28.
DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; JE, joint effusion; MCPs, metacarpophalangeal
joints; PD, power Doppler-assessed synovial vascularisation; SH, hypoechoic synovial hyperplasia; SJC, swollen joint count; TJC, tender joint
count.
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